Aptose Biosciences (APTO) Regains Nasdaq Compliance

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO) today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is in compliance with Nasdaq’s minimum bid price requirement.

On March 14, 2025, Nasdaq confirmed that, for ten consecutive business days, the closing bid price of the Company’s common shares has been $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2). Separately, Aptose is not in compliance with the $2.5 million requirement and is operating under an exception granted by the Hearing Panel, which provides additional time to regain compliance, although there is no assurance that the Company will successfully achieve full compliance with the Nasdaq shareholders equity compliance requirements.

You May Also Be Interested In

• Getty Realty discloses separation terms for departing accounting officer
• BKV Corporation (BKV) files for 5.315M share offering by selling stockholders
• QNB Corp. overallotment option adds 160,714 shares at $42 each